Steve Blakemore

Vice President, Translational Medicine

Professional Overview
Steve Blakemore is an accomplished senior leader in the biopharmaceutical industry, with over 15 years of experience driving translational research and development initiatives. As the Vice President of Translational Medicine, he leverages his deep expertise in oncology and molecular medicine to guide the strategic translation of early-stage discoveries into viable clinical candidates.

Experience Summary

Current Role
As the Vice President of Translational Medicine at Accent Therapeutics, Inc., Steve is responsible for overseeing the company's translational research and development programs. He collaborates closely with cross-functional teams to identify and validate novel therapeutic targets, design efficient translational strategies, and accelerate the progression of promising drug candidates through preclinical and clinical milestones. Under his leadership, Accent Therapeutics has advanced multiple oncology programs into clinical development, contributing to the company's growing pipeline and industry impact.

Career Progression
Prior to joining Accent Therapeutics, Steve held progressive leadership roles in translational medicine and oncology research at notable biopharmaceutical companies, including Bicycle Therapeutics, Epizyme, Millennium The Takeda Oncology Company, and GlaxoSmithKline. In these positions, he spearheaded the development of innovative diagnostic and therapeutic approaches, driving significant advancements in the understanding and treatment of various cancer types.

Academic Background
Steve holds a Ph.D. in Molecular and Cellular Biology from the University of Pennsylvania, where he specialized in oncology and molecular medicine. His academic achievements include published research in high-impact peer-reviewed journals and recognition from industry organizations for his contributions to the field.

Areas of Expertise

• Translational research and development in oncology

• Biomarker discovery and validation

• Molecular diagnostics and companion diagnostics

• Investigational new drug (IND) and clinical trial design

• Cross-functional team leadership and collaboration

Professional Impact
During his career, Steve has played a pivotal role in the advancement of several oncology drug candidates, including the successful IND submission and initiation of multiple clinical trials. His research and discoveries have resulted in the development of novel biomarkers and diagnostic tools that have enhanced patient stratification and improved treatment outcomes. Steve's expertise and leadership have been instrumental in driving the growth and success of the organizations he has served.

Conclusion
With his extensive experience, proven track record, and collaborative approach, Steve Blakemore is a valuable asset in the biopharmaceutical industry. As the Vice President of Translational Medicine at Accent Therapeutics, he continues to make significant contributions to the advancement of innovative cancer therapies and diagnostics, positioning the company for long-term success and meaningful impact on patient lives.